info@marketresearchfuture.com   📞 +1 (855) 661-4441(US)   📞 +44 1720 412 167(UK)   📞 +91 2269738890(APAC)

Henry Schein Increases its Portfolio in Several of Dentistry's Fastest-growing Categories, Including Clinical Software, Oral Surgery, and Orthodontic Products

By Rahul Gotadki , 21 December, 2022

The shareholders of Biotech Dental S.A.S., a rapidly expanding provider of cutting-edge clinical software and oral surgery and orthodontic products based in Salon-de-Provence, France, have signed a definitive agreement with Henry Schein, Inc., the world's largest provider of health care solutions to office-based medical and dental professionals, to acquire a major share stake in the business.

Henry Schein and Biotech Dental will expand the number of dentists, dental labs, and geographic areas that have access to Biotech Dental's complete line of high-quality software, products, and services, including dental prostheses, clear aligners, dental implants, regenerative solutions, and biomaterials. This transaction's implementation is dependent on receiving certain regulatory approvals.

Nemotec, a complete, integrated suite of planning and diagnostic software using an open architecture that connects dispersed devices to provide a digital view of the patient's overall health condition, offering greater diagnostic accuracy and an enhanced care experience, is one of several effective solutions supplied by Biotech Dental. In addition to producing the Smilers® brand of clear aligners, Biotech Dental is one of the brands with the fastest growth in France for custom abutments and implants. Moreover, LaGalaxy, a comprehensive, open, and secure software platform where both clinical and administrative procedures can be carried out, has been developed by Biotech Dental. Dentists and dentistry labs have access to end-to-end integrated technological platforms on a single platform that cut the price of implants, orthodontic, and prosthetic treatments while reducing treatment times and costs and helping to enhance case outcomes.

In accordance with the terms of the deal, Henry Schein will acquire a controlling interest in Biotech Dental. The remaining minority stake in the business will stay under the ownership of Upper side Capital Partners Group. The revenue for Biotech Dental's fiscal year 2021 was over $100 million. When amortization is not considered, Henry Schein anticipates that this deal will marginally erode 2023 profits per share. Non-cash acquisition accounting adjustments for inventories are the leading cause of the dilution. Financial information wasn’t publicly disclosed.
 

                Dental Implants Placed By General Practitioners Vs. Specialists in the US         

Placement.jpg

Latest News

2050.png
Big Tech Backs Nuclear Expansion: Pledges to Triple Global Capacity by 2050

Leading technology giants Amazon, Google, and Meta have teamed up with other big energy users in a historic action at the CERAWeek 2025 energy conference in Houston to promote an ambitious initiative: doubling world nuclear power capacity by 2025…

Read More

Shifts.png
China’s Refining Industry Sees 2.1% Growth in Early 2025 Amid Rising Fuel Demand and Geopolitical Shifts

China's refining sector showed resilience and adaptability in the first months of 2025, raising crude oil throughput by 2.1 percent over the year before. According to the National Bureau of Statistics, this increase resulted in a processing volume of…

Read More

2025.png
Elsevier Unveils ScienceDirect AI in 2025 to Revolutionize Research Efficiency

In March 2025, Elsevier launched ScienceDirect AI, a world-renowned leader in science and health information science. This state-of-the-art generative AI tool can potentially transform the industry with its revolutionary advances in research. This…

Read More

Drop.png
EV Revolution: Battery Prices Drop Below USD 100/kWh Amid China's Dominance of the Market in 2025

The global electric vehicle (EV) industry has reached a pivotal milestone. The average price of lithium-ion battery packs has dropped below the USD 100 per kilowatt-hour (kWh) threshold, a benchmark long considered critical for achieving price parity…

Read More

2025.png
China Accelerates Push for Domestic EV Chips Amid Global Trade Tensions in 2025

In 2025, China will focus on self-sufficiency in high-tech industries by further integrating domestically produced semiconductor chips into the country\'s electric vehicle (EV) industry. By doing so, China aims to reduce reliance on foreign…

Read More

Author Pic
Rahul Gotadki

Assistant Manager